Sedana Medical (OM:SEDANA) Stock Valuation, Peer Comparison & Price Targets

Share Price vs Fair Value

What is the Fair Price of SEDANA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SEDANA (SEK12.52) is trading below our estimate of fair value (SEK42.62)

Significantly Below Fair Value: SEDANA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SEDANA?

Key metric: As SEDANA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SEDANA. This is calculated by dividing SEDANA's market cap by their current revenue.
What is SEDANA's PS Ratio?
PS Ratio	7.1x
Sales	SEK 174.14m
Market Cap	SEK 1.24b

SEDANA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.9x
Enterprise Value/EBITDA	-19.7x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does SEDANA's PS Ratio compare to its peers?

The above table shows the PS ratio for SEDANA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
CARE Careium	0.8x	10.2%	SEK 705.5m
CRAD B C-Rad	2x	14.8%	SEK 958.7m
PAX Paxman	5.3x	30.0%	SEK 1.3b
STIL Stille	3.9x	14.2%	SEK 1.9b
SEDANA Sedana Medical	7.1x	27.8%	SEK 1.2b

Price-To-Sales vs Peers: SEDANA is expensive based on its Price-To-Sales Ratio (7.1x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does SEDANA's PS Ratio compare vs other companies in the SE Medical Equipment Industry?

12 Companies	Price / Sales	Estimated Growth	Market Cap
ARJO B Arjo	0.8x	3.7%	US$844.23m
CARE Careium	0.8x	10.2%	US$64.16m
BOUL Boule Diagnostics	0.5x	6.4%	US$24.72m
ARCOMA Arcoma	0.9x	8.3%	US$13.37m

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: SEDANA is expensive based on its Price-To-Sales Ratio (7.1x) compared to the Swedish Medical Equipment industry average (4.4x).

Price to Sales Ratio vs Fair Ratio

What is SEDANA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SEDANA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7.1x
Fair PS Ratio	6.6x

Price-To-Sales vs Fair Ratio: SEDANA is expensive based on its Price-To-Sales Ratio (7.1x) compared to the estimated Fair Price-To-Sales Ratio (6.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SEDANA forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	SEK 12.52	SEK 26.50 +111.7%	9.4%	SEK 29.00	SEK 24.00	n/a	2
Nov ’25	SEK 11.44	SEK 24.50 +114.2%	2.0%	SEK 25.00	SEK 24.00	n/a	2
Oct ’25	SEK 23.30	SEK 36.00 +54.5%	19.4%	SEK 43.00	SEK 29.00	n/a	2
Sep ’25	SEK 23.40	SEK 36.00 +53.8%	19.4%	SEK 43.00	SEK 29.00	n/a	2
Aug ’25	SEK 22.85	SEK 36.00 +57.5%	19.4%	SEK 43.00	SEK 29.00	n/a	2
Jul ’25	SEK 23.30	SEK 35.50 +52.4%	21.1%	SEK 43.00	SEK 28.00	n/a	2
Jun ’25	SEK 27.00	SEK 35.50 +31.5%	21.1%	SEK 43.00	SEK 28.00	n/a	2
May ’25	SEK 22.65	SEK 35.50 +56.7%	21.1%	SEK 43.00	SEK 28.00	n/a	2
Apr ’25	SEK 16.01	SEK 35.50 +121.7%	29.6%	SEK 46.00	SEK 25.00	n/a	2
Mar ’25	SEK 17.52	SEK 35.50 +102.6%	29.6%	SEK 46.00	SEK 25.00	n/a	2
Feb ’25	SEK 20.54	SEK 43.00 +109.3%	7.0%	SEK 46.00	SEK 40.00	n/a	2
Jan ’25	SEK 23.16	SEK 43.00 +85.7%	7.0%	SEK 46.00	SEK 40.00	n/a	2
Dec ’24	SEK 20.70	SEK 43.00 +107.7%	7.0%	SEK 46.00	SEK 40.00	n/a	2
Nov ’24	SEK 19.27	SEK 43.00 +123.1%	7.0%	SEK 46.00	SEK 40.00	SEK 11.44	2
Oct ’24	SEK 18.83	SEK 58.00 +208.0%	13.8%	SEK 66.00	SEK 50.00	SEK 23.30	2
Sep ’24	SEK 19.35	SEK 58.00 +199.7%	13.8%	SEK 66.00	SEK 50.00	SEK 23.40	2
Aug ’24	SEK 23.24	SEK 64.00 +175.4%	21.9%	SEK 78.00	SEK 50.00	SEK 22.85	2
Jul ’24	SEK 27.04	SEK 69.00 +155.2%	27.5%	SEK 88.00	SEK 50.00	SEK 23.30	2
Jun ’24	SEK 29.48	SEK 69.00 +134.1%	27.5%	SEK 88.00	SEK 50.00	SEK 27.00	2
May ’24	SEK 25.76	SEK 69.00 +167.9%	27.5%	SEK 88.00	SEK 50.00	SEK 22.65	2
Apr ’24	SEK 21.38	SEK 70.00 +227.4%	28.6%	SEK 90.00	SEK 50.00	SEK 16.01	2
Mar ’24	SEK 22.50	SEK 70.00 +211.1%	28.6%	SEK 90.00	SEK 50.00	SEK 17.52	2
Feb ’24	SEK 22.66	SEK 72.00 +217.7%	30.6%	SEK 94.00	SEK 50.00	SEK 20.54	2
Jan ’24	SEK 18.70	SEK 72.00 +285.0%	30.6%	SEK 94.00	SEK 50.00	SEK 23.16	2
Dec ’23	SEK 18.45	SEK 72.00 +290.2%	30.6%	SEK 94.00	SEK 50.00	SEK 20.70	2
Nov ’23	SEK 20.30	SEK 72.00 +254.7%	30.6%	SEK 94.00	SEK 50.00	SEK 19.27	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Arcoma

SEK 146.4m

Develops, produces, and provides radiology solutions worldwide.

ARCOMA

SEK 11.15

7D

6.2%

1Y

53.8%

Mentice

SEK 560.0m

Provides endovascular simulation technology solutions in Europe, the Middle East, Africa, Asia, the Asia Pacific region, and the Americas.

MNTC

SEK 22.80

7D

8.6%

1Y

-44.7%

Dignitana

SEK 95.8m

A medical technology company, engages in the development, production, and marketing of medical cooling devices in the United States and internationally.

DIGN

SEK 1.23

7D

11.8%

1Y

-42.8%

Sedana Medical Valuation